Society of Hematologic Oncology’s Seventh Annual Meeting

Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial

Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid...

Cardiac, vascular and hypertension treatment-emergent adverse events (TEAE) rates were similarly low with the tyrosine kinase inhibitors (TKIs) bosutinib and imatinib
Outcome of Pregnancy in CML Patients in Chronic Phase with Different Molecular Response, Single Centre Experience

Outcome of Pregnancy in CML Patients in Chronic Phase with Different Molecular Response, Single...

Pregnant patients with chronic myeloid leukemia (CML) should be treated according to major molecular response (MMR) and complete molecular response (CMR) to treatment
Inflammatory and Immune Manifestations in Patients with Chronic Myelomonocytic Leukemia

Inflammatory and Immune Manifestations in Patients with Chronic Myelomonocytic Leukemia

Assessing the therapeutic management of immune manifestations associated with chronic myelomonocytic leukemia (CMML) remains a challenging task.
hiv

The Clinical Significance of JAK2V617F Mutation for Philadelphia–Negative Chronic Myeloproliferative Neoplasms in Patients with...

Researchers have confirmed that simple and rapid JAK2V617F peripheral blooding testing is a vital component of diagnosis latent myeloproliferative disease (MPD) and splanchnic vein thrombosis (SVT).
Prognostic Impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients

Prognostic Impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients

Among Egyptian patients, early identification additional chromosomal abnormalities (ACAs) in Ph+ metaphases in chronic phase chronic myeloid leukemia (CP-CML) is clinically important and predicts response to tyrosine kinase inhibitor (TKI) therapy

Hematology and Oncology News

Curated Journal Abstracts

click me